12.72

1.78% -0.23

After Hours: 12.72

Atrium Therapeutics Inc (RNA)

Overview News Price History Option Chain Financials Discussions Forecast

Atrium Therapeutics Inc stock is traded at $12.72, with a volume of 168.12K. It is down -1.78% in the last 24 hours and down -11.05% over the past month. Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.

Previous Close:

$12.95

Open:

$12.94

24h Volume:

168.12K

Relative Volume:

0.15

Market Cap:

$217.58M

Revenue:

$10.73M

Net Income/Loss:

$-455.74M

P/E Ratio:

-5.3558

EPS:

-2.375

Net Cash Flow:

$-502.70M

1W Performance:

-4.36%

1M Performance:

-11.05%

6M Performance:

-82.00%

1Y Performance:

-59.80%

1-Day Range:

$12.61

$13.01

1-Week Range:

$12.61

$13.97

52-Week Range:

$11.95

$73.06

Atrium Therapeutics Inc Stock (RNA) Company Profile

Name

Atrium Therapeutics Inc

Sector

Healthcare (1099)

Industry

Biotechnology (615)

Phone

858-401-7900

Address

3020 CALLAN ROAD, SAN DIEGO, CA

Employee

391

Twitter

Next Earnings Date

2024-12-07

Latest SEC Filings

RNA's Discussions on Twitter

Compare RNA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RNA Atrium Therapeutics Inc	12.72	221.52M	10.73M	-455.74M	-502.70M	-2.375
VRTX Vertex Pharmaceuticals Inc	430.44	110.81B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	649.76	66.02B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	804.25	48.27B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.48	38.22B	4.29B	577.22M	641.34M	4.2086
ONC Beone Medicines Ltd Adr	308.74	30.41B	5.76B	514.49M	1.10B	4.4813

Atrium Therapeutics Inc Stock (RNA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-11-26	Initiated	Wells Fargo	Overweight
Sep-17-25	Initiated	Roth Capital	Buy
Jul-10-25	Resumed	Goldman	Buy
Jun-24-25	Initiated	Bernstein	Outperform
Jun-17-25	Initiated	Wolfe Research	Outperform
Jun-11-25	Initiated	Raymond James	Strong Buy
Mar-13-25	Initiated	Citigroup	Buy
Mar-12-25	Initiated	BMO Capital Markets	Outperform
Mar-07-25	Initiated	Scotiabank	Sector Outperform
Dec-20-24	Initiated	H.C. Wainwright	Buy
Nov-26-24	Initiated	RBC Capital Mkts	Outperform
Sep-24-24	Initiated	Goldman	Buy
Aug-28-24	Initiated	Barclays	Overweight
May-03-24	Initiated	BofA Securities	Buy
Mar-14-24	Initiated	Cantor Fitzgerald	Overweight
May-22-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-31-23	Downgrade	Evercore ISI	Outperform → In-line
Jul-20-22	Initiated	Chardan Capital Markets	Buy
Jul-12-22	Initiated	Raymond James	Strong Buy
Sep-07-21	Initiated	Evercore ISI	Outperform
Jun-17-21	Initiated	Needham	Buy
Apr-26-21	Resumed	Credit Suisse	Outperform
Jul-07-20	Initiated	Cowen	Outperform
Jul-07-20	Initiated	Credit Suisse	Outperform
Jul-07-20	Initiated	SVB Leerink	Outperform
Jul-07-20	Initiated	Wells Fargo	Overweight

View All

Atrium Therapeutics Inc Stock (RNA) Latest News

May 19, 2026

RNA Price Today: Atrium Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC

May 19, 2026

May 16, 2026

RNA Initiated Coverage by Leerink Partners -- Rating Set to Outp - GuruFocus

May 16, 2026

May 15, 2026

RA Capital (RNA) healthcare fund discloses 864,102 shares, 5.6% stake - Stock Titan

May 15, 2026

Leerink initiates Atrium Therapeutics stock with outperform rating By Investing.com - Investing.com Canada

May 15, 2026

Leerink Partners Initiates Atrium Therapeutics(RNA.US) With Buy Rating, Announces Target Price $25 - Moomoo

May 15, 2026

Leerink Partners Initiates Coverage on Atrium Therapeutics With Outperform Rating, $25 PT - Moomoo

May 15, 2026

RNA Stock Price, Quote & Chart | ATRIUM THERAPEUTICS INC (NASDAQ:RNA) - ChartMill

May 15, 2026

Atrium Therapeutics 1Q Loss/Shr 97c >RNA - Moomoo

May 15, 2026

May 14, 2026

Atrium Therapeutics Reports First Quarter 2026 Financial Results - Investing News Network

May 14, 2026

Atrium Therapeutics 1Q Rev $19.6M >RNA - Moomoo

May 14, 2026

Atrium Therapeutics Believes Cash Resources Sufficient to Fund Planned Ops Through Key Clinical Proof-Of-Concept Milestones >RNA - Moomoo

May 14, 2026

Atrium Therapeutics (RNA) Q1 2026: milestone revenue, higher R&D and $267.8M cash - Stock Titan

May 14, 2026

Atrium Therapeutics Reports Q1 2026 Financial Results and Corporate Progress - Intellectia AI

May 14, 2026

Atrium Therapeutics reports Q1 2026: $19.6M collaboration revenue, $267.8M cash - TradingView

May 14, 2026

Atrium Therapeutics, Inc. 1Q 2026: Revenue $19.6M, EPS $(0.97) — 10-Q Summary - TradingView

May 14, 2026

Atrium Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 14, 2026

Atrium Therapeutics Q1 collaboration revenue surges after spin-off - TradingView

May 14, 2026

Atrium Therapeutics (Nasdaq: RNA) Q1 2026 results show higher revenue and loss - Stock Titan

May 14, 2026

Fierce Biotech Fundraising Tracker '26: Create corrals $122M; Isomorphic's $2B series B - Fierce Biotech

May 14, 2026

May 11, 2026